| PPP1R9A Gene | |
|---|---|
| Protein Phosphatase 1 Regulatory Subunit 9A | |
| Gene Symbol | PPP1R9A |
| Full Name | Protein Phosphatase 1 Regulatory Subunit 9A |
| Alternative Names | Neurabin-1, Spinophilin |
| Chromosomal Location | 7q21.3 |
| NCBI Gene ID | [55697](https://www.ncbi.nlm.nih.gov/gene/55697) |
| OMIM | [602321](https://www.omim.org/entry/602321) |
| Ensembl ID | [ENSG00000116489](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116489) |
| UniProt ID | [Q9Y5X4](https://www.uniprot.org/uniprot/Q9Y5X4) |
| Protein Class | Phosphatase Regulatory Subunit |
| Pathway | [Synaptic Plasticity](/mechanisms/synaptic-plasticity) |
PPP1R9A (Protein Phosphatase 1 Regulatory Subunit 9A), also known as Neurabin-1 or Spinophilin, is a neuron-specific regulatory protein that plays critical roles in synaptic plasticity, dendritic spine morphogenesis, and learning and memory[1]. It is a key scaffold protein that localizes protein phosphatase 1 (PP1) to synaptic sites, where it regulates the phosphorylation state of various synaptic proteins[2].
The name "spinophilin" derives from its high concentration in dendritic spines, the small protrusions from neurons that receive the majority of excitatory synaptic inputs. Neurabin-1 serves as a critical link between the actin cytoskeleton and synaptic signaling, making it essential for proper synaptic function and plasticity[3].
Neurabin-1 contains several distinct structural domains that mediate its synaptic functions:
The RVXF motif in neurabin-1 is the critical PP1-recruitment domain. This consensus sequence (Arg-Val-Phe-any) is present in most PP1 regulatory subunits and allows competitive binding to the PP1 catalytic site, regulating its activity toward specific substrates[4].
Neurabin-1 performs several essential functions in PP1 targeting:
The spatial regulation of PP1 by neurabin-1 is critical for synaptic plasticity. By locally controlling protein phosphorylation states, neurabin-1 influences receptor trafficking, ion channel function, and cytoskeletal dynamics in dendritic spines.
Neurabin-1-targeted PP1 dephosphorylates several key synaptic proteins:
This broad substrate specificity makes neurabin-1 a master regulator of synaptic function.
Neurabin-1 interacts with numerous synaptic proteins:
PPP1R9A expression is highly restricted:
During development:
Neurabin-1 has emerging roles in Alzheimer's disease pathogenesis[5]:
Synaptic loss: The loss of dendritic spines and synaptic connections is the strongest correlate of cognitive decline in AD. Neurabin-1, as a critical regulator of spine morphology and function, may be central to this process.
AMPA receptor trafficking: In AD, altered AMPA receptor trafficking contributes to synaptic dysfunction. Neurabin-1 directly regulates AMPA receptor endocytosis and recycling through PP1-mediated dephosphorylation.
Tau pathology: Hyperphosphorylated tau can disrupt synaptic function through multiple mechanisms. Studies suggest that tau accumulation may interfere with neurabin-1 targeting to spines.
Therapeutic implications: Enhancing neurabin-1 function could potentially protect synapses in AD by:
In Parkinson's disease, neurabin-1 may be important for dopaminergic signaling[6]:
Dopamine receptor signaling: Neurabin-1 interacts with dopamine receptors and regulates their signaling through PP1. This is particularly relevant in the striatum, where dopaminergic inputs from the substantia nigra modulate motor control.
Synaptic plasticity in basal ganglia: The basal ganglia circuits rely heavily on synaptic plasticity for motor learning. Neurabin-1-mediated PP1 regulation is crucial for this plasticity.
L-DOPA-induced dyskinesia: Abnormal synaptic plasticity in striatal neurons contributes to L-DOPA-induced dyskinesia in PD patients. Targeting neurabin-1/PP1 signaling may provide therapeutic benefits.
PPP1R9A is associated with autism spectrum disorder[7]:
Genetic associations: Rare variants in PPP1R9A have been identified in ASD patients
Synaptic dysfunction: Altered neurabin-1 expression or function could disrupt synaptic development and plasticity
Shared pathways: Many ASD-risk genes encode synaptic proteins, suggesting shared pathophysiology
PPP1R9A associations with schizophrenia have been investigated[8]:
Genetic findings: Some studies report associations between PPP1R9A variants and schizophrenia risk
Postmortem studies: Altered neurabin-1 expression has been observed in schizophrenia brains
Therapeutic implications: Antipsychotic drugs may affect PP1 signaling pathways
Neurabin-1 plays complex roles in long-term potentiation (LTP):
Early phase LTP: Initial LTP involves modification of existing synaptic proteins. Neurabin-1/PP1 regulates the phosphorylation state of AMPA receptors during this phase.
Late phase LTP: Gene expression required for late LTP may involve changes in neurabin-1 expression or localization.
Metaplasticity: The overall capacity for LTP is modulated by basal PP1 activity, regulated by neurabin-1.
Similarly, long-term depression (LTD) requires neurabin-1:
AMPA receptor internalization: LTD involves AMPA receptor removal from synapses, a process regulated by PP1-mediated dephosphorylation
Actin cytoskeleton: Spine shrinkage during LTD requires actin cytoskeleton remodeling, which neurabin-1 regulates
Neurabin-1 is essential for dendritic spine development[@housse2013]:
Targeting neurabin-1/PP1 signaling offers therapeutic opportunities:
Small molecule modulators: Compounds that enhance neurabin-1/PP1 interactions could improve synaptic function
Gene therapy: Viral vector delivery to increase neurabin-1 expression in vulnerable brain regions
Protein-protein interaction inhibitors: In conditions where excessive PP1 activity is detrimental
Potential applications include:
Studies of PPP1R9A utilize:
Feng J, et al. Neurabin in spine development. Journal of Neuroscience. 2000. ↩︎
Oliver CJ, et al. Neurabin: a synapse-specific PP1 regulator. Nature. 2002. ↩︎
Benned-Jensen T, Smith RJ. Neurabin regulation of synaptic function. Journal of Neurochemistry. 2013. ↩︎
Greengard P, et al. The neurobiology of slow synaptic transmission. Science. 2001. ↩︎
Yan Z, et al. Synaptic dysfunction in Alzheimer's disease. Nature Reviews Neuroscience. 2019. ↩︎
Huang L, et al. PP1 in dopaminergic signaling. Journal of Neurochemistry. 2019. ↩︎
Zhou X, et al. PPP1R9A and neuropsychiatric disorders. Molecular Psychiatry. 2019. ↩︎
Smith KE, et al. Neurabin and psychiatric disease. Molecular Psychiatry. 2013. ↩︎